High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

Journal Article (Clinical Trial;Journal Article)

The purpose of this study was to determine the maximally tolerated dose of doxorubicin administered during two cycles of intensive chemotherapy with cyclophosphamide and doxorubicin without stem cell support in patients with advanced cancer and to assess the cumulative cardiac toxicity of the regimen by noninvasive radionuclide imaging and by pre-and postchemotherapy endomyocardial biopsies. Thirty-eight patients (thirty-six with high risk or metastatic breast cancer) were treated in a dose-escalation trial using a fixed dose of i.v. cyclophosphamide (4.2 g/m2) administered over 2 h on day 5 and escalating doses of doxorubicin (50-175 mg/m2) given as a 96-h continuous i.v. infusion on days 1-4, using Filgrastim (granulocyte colony-stimulating factor) for hematological support beginning on day 6. All patients underwent pretreatment, and 28 patients underwent postchemotherapy endomyocardial biopsies. Twenty-nine of 38 patients received two cycles of treatment (median number of days between cycles, 44; range, 34-62). Twenty-one patients had received doxorubicin previously at cumulative dose levels

Full Text

Duke Authors

Cited Authors

  • Morgan, RJ; Doroshow, JH; Venkataraman, K; Chang, K; Raschko, J; Somlo, G; Leong, L; Tetef, M; Shibata, S; Hamasaki, V; Margolin, K; Forman, S; Akman, S; Coluzzi, P; Ahn, C; Weiss, L; Gadgil, U; Harrison, J

Published Date

  • December 1997

Published In

Volume / Issue

  • 3 / 12 Pt 1

Start / End Page

  • 2337 - 2345

PubMed ID

  • 9815632

International Standard Serial Number (ISSN)

  • 1078-0432


  • eng

Conference Location

  • United States